Micheliolide is primarily investigated for its anti-inflammatory and anti-cancer properties. It shows promise in targeting pathways involved in chronic inflammation, making it a candidate for development in treating inflammatory diseases such as colitis. In oncology, Micheliolide demonstrates activity against leukemia and solid tumors by inducing apoptosis and inhibiting tumor cell proliferation. It can cross the blood-brain barrier, which enhances its potential for treating brain cancers. Additionally, it has been studied for its ability to modulate immune responses and reduce oxidative stress, suggesting possible applications in neurodegenerative conditions. Research is ongoing to improve its stability and delivery through prodrug formulations.